Stevens-Johnson syndrome (SJS) is a rare, potentially fatal drug reaction in which the skin and mucous membranes blister and slough off, essentially behaving like a severe burn triggered from the inside. It sits on a spectrum with an even more dangerous condition called toxic epidermal necrolysis (TEN), separated mainly by how much skin is involved: SJS affects less than 10% of the body surface area, while TEN exceeds 30%, and cases in between are classified as overlap SJS/TEN.1Europe PMC / StatPearls. Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) : Immunologic Reactions Despite its rarity, SJS deserves attention because it can be set off by commonly prescribed medications, and the window between early warning signs and life-threatening damage is narrow.
What Triggers SJS
The overwhelming majority of SJS cases are caused by medications. The drug classes most frequently implicated include antibiotics (especially sulfonamide antibiotics like trimethoprim-sulfamethoxazole), anticonvulsants, anti-gout drugs, painkillers in the NSAID family, and certain cancer medications.2PubMed Central. A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis The reaction does not depend on the dose being too high. Instead, it is an aberrant immune response: the drug or one of its breakdown products triggers the immune system to attack the skin itself.
A landmark study quantified the risk tied to specific drugs. For medications taken short-term, sulfonamide antibiotics carried the highest relative risk, followed by cephalosporins and quinolone antibiotics. For drugs taken over months or years, the danger was concentrated in the first two months of use. Carbamazepine, phenytoin, phenobarbital, allopurinol, and oxicam-type NSAIDs all carried dramatically elevated risk during that initial window, with relative risks ranging from roughly 25 to 90 compared to non-users.3PubMed. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis That early-exposure pattern is one of the reasons SJS catches people off guard: the reaction often appears within the first weeks of starting a new prescription, before anyone has reason to suspect a problem.
A population-based study confirmed phenytoin, lamotrigine, and allopurinol as the drugs with the highest absolute risk per new user, while also flagging sunitinib (a cancer drug), sulfasalazine, and carbamazepine.4PubMed Central. Culprit Medications and Risk Factors Associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case-Control Study Anti-epileptic drugs as a class carry roughly nine times the SJS/TEN risk compared to other medications, though the risk varies substantially between individual drugs in that class, with at least six carrying risk estimates over 20 times baseline.5PubMed Central. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System
Infections can also trigger SJS, particularly in children. Mycoplasma pneumoniae, the bacterium behind “walking pneumonia,” is the most commonly identified infectious trigger. In a comparative study of pediatric cases, children whose SJS was triggered by Mycoplasma tended to be older (median age around 9 years) than those whose cases were drug-induced (median age around 3.5 years), and half the Mycoplasma group showed lung consolidation or pleural effusion on chest imaging.6PubMed Central. Comparative analysis of Mycoplasma Pneumoniae and Drug-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Children This distinction matters because infection-triggered cases may respond differently to treatment and tend to have somewhat better outcomes than drug-triggered cases.
Why the Immune System Attacks the Skin
SJS is fundamentally an immune overreaction. The culprit drug, or a molecule produced as the body metabolizes it, gets presented to the immune system in a way that marks the skin’s own cells as targets. Cytotoxic T cells and natural killer cells then flood the skin and release a protein called granulysin, which has been identified as a key mediator of the widespread skin cell death that defines the disease.7Allergology International. Genetic Markers and Danger Signals in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis In practical terms, the body treats its own skin the way it would treat a patch of virus-infected tissue: it kills it off.
This explains the characteristic appearance. What starts as flu-like malaise and a spreading, painful rash quickly progresses to blistering. The top layer of skin separates from the layers beneath, sometimes in large sheets. Mucous membranes in the mouth, eyes, and genitals are almost always involved. On biopsy, pathologists see dead skin cells, separation of the skin layers, and inflammatory cells flooding into the tissue.8Europe PMC / Mayo Clinic Proceedings. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic One diagnostic difficulty is that no internationally standardized criteria exist, and reliable blood markers for catching SJS early are still lacking.9J-STAGE / Allergology International. Recent advances in the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis
Genetic Risk and Who Is Vulnerable
Not everyone who takes a high-risk drug develops SJS, and genetics are a big part of why. Specific variations in the HLA genes, which govern how the immune system recognizes foreign substances, dramatically increase a person’s susceptibility. The associations are often drug-specific: certain HLA variants make a person far more likely to react to one particular medication but not others.
For NSAID-triggered SJS, for example, the HLA-DQB1*03:02 variant is associated with roughly a ninefold increase in risk, and the association is even stronger for piroxicam specifically.10PubMed Central. Genetic Variants Associated with Non-Steroidal Anti-Inflammatory Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis The best-known example is the HLA-B*15:02 allele, which is common in Southeast Asian populations and strongly predicts carbamazepine-induced SJS. The discovery of these risk alleles has opened the door to genetic screening before prescribing high-risk drugs, and demonstration that such screening actually reduces cases has strengthened the case for broader implementation.11PubMed Central. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis
In practice, HLA-B*15:02 testing before starting carbamazepine is now standard in many countries with large Southeast Asian populations, and some guidelines recommend it more broadly. Similar screening strategies for allopurinol (using HLA-B*58:01) are increasingly adopted as well. The hope is that pharmacogenomic testing will eventually extend to more drugs and more populations, catching vulnerable patients before they ever take the triggering medication. The challenge is that many drug-HLA associations are population-specific, so a test that works well in one ethnic group may miss risk in another.
How SJS Is Treated
There is no antidote for SJS. Treatment centers on three priorities: stopping the offending drug immediately, aggressive supportive care, and managing the raw, exposed skin.
The single most important step is identifying and withdrawing the culprit medication as fast as possible. Every day of continued exposure worsens the reaction. After that, the evidence strongly supports transferring patients to a specialized burn unit, where teams have the expertise and equipment to handle large-area skin loss, fluid management, infection control, and pain.12PubMed Central. Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review Wound care protocols involving removal of blistered skin and closure with synthetic or biological dressings have been associated with improved survival compared to predicted outcomes.13PubMed. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience
Beyond wound care, the use of immune-suppressing drugs to halt the runaway immune attack remains genuinely controversial. Systemic corticosteroids and intravenous immunoglobulin (IVIg) have been debated for decades, with studies pointing in different directions. More recently, cyclosporine and biologic agents targeting a molecule called TNF-alpha have shown promise in a growing number of studies.14PubMed Central. A Review of the Systemic Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Part of the difficulty in settling these debates is the rarity of SJS itself: running a large randomized trial is nearly impossible when cases are so infrequent, so evidence accumulates slowly from case series and small comparative studies.
Predicting Who Will Survive
Doctors use scoring systems to estimate mortality risk once SJS or TEN is diagnosed. The most widely used tool, SCORTEN, assigns points based on factors like age, heart rate, percentage of skin detachment, blood urea nitrogen level, serum bicarbonate, blood glucose, and presence of cancer. Higher scores correspond to higher predicted mortality, and a meta-analysis found that SCORTEN performs reasonably well as a predictor overall.15PubMed. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis
That said, these tools have recognized blind spots. They can overestimate mortality in some populations and underestimate it in others, and they were not designed to track whether a patient is getting better or worse over time, only to give a snapshot at admission.16PubMed Central. Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis A newer tool called ABCD-10 has been introduced as an alternative, but it too is imperfect. The mortality range for SJS/TEN overall spans from low single digits for mild SJS to over 30% for extensive TEN, depending heavily on the patient’s age, comorbidities, and speed of treatment.
Eye Damage and Why Early Treatment Matters
The eyes are among the most vulnerable targets in SJS. Ocular involvement is common and can range from mild conjunctivitis to devastating scarring of the cornea and surrounding tissues that leads to chronic dry eye, light sensitivity, and even blindness.17PubMed. Amniotic membrane transplantation techniques in acute ocular Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review What makes ocular SJS particularly cruel is that the worst damage often becomes apparent only after the acute crisis has passed, as scarring and chronic inflammation set in over weeks to months.
Amniotic membrane transplantation, where a thin biological membrane harvested from human placentas is placed over the eye surface during the acute stage, has emerged as an important early intervention. The membrane suppresses inflammation and promotes healing of the eye’s surface layer. Studies indicate it can prevent or reduce the severe dry eye, scarring, and light sensitivity that would otherwise follow.18PubMed Central. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis The key is timing: this works best when done early, during the acute phase, rather than after scarring has already taken hold. Getting an ophthalmologist involved from the start of a suspected SJS case is now considered essential, though in practice it does not always happen, especially at hospitals without the specialist on hand.
Long-Term Consequences for Survivors
Surviving the acute phase of SJS does not mean the story is over. In a study of long-term outcomes, the most common lasting physical problems were skin changes (reported by about 84% of survivors), followed by eye problems (about 60%) and oral mucosal issues (roughly 51%).19JAMA Dermatology. Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Skin complications include discoloration, scarring, and abnormal nail regrowth. Oral problems range from chronic dryness to gum disease and tooth decay triggered by the damage to the mouth lining.
The psychological toll is equally heavy. Following discharge, many survivors report deep anxiety around taking any medication again, which is understandable given that a pill they trusted nearly killed them. Some develop avoidance behavior toward doctors and pharmacies. Symptoms consistent with post-traumatic stress disorder, anxiety, and depression are well documented in this population.20PubMed Central. The psychological impact of Stevens–Johnson syndrome and toxic epidermal necrolysis on patients’ lives: a Critically Appraised Topic The fear of medications creates a practical dilemma: many SJS survivors still need treatment for the conditions that led to the offending prescription in the first place, whether epilepsy, gout, or infection. Navigating which drugs are safe to take afterward requires careful specialist guidance and sometimes formal drug allergy testing.
SJS in Children
SJS occurs in children as well as adults, though the triggering pattern differs somewhat by age. In children, infections play a larger relative role compared to adults. Mycoplasma pneumoniae is a frequent culprit, particularly in school-age children. Among drug-triggered pediatric cases, antibiotics and NSAIDs are the most common offenders, which partly reflects the drugs children are most likely to be exposed to.21PubMed Central. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis
In a large pediatric cohort, mucosal involvement was seen in about 69% of cases, and prior drug exposure was documented in roughly 79%, with antibiotics and NSAIDs accounting for nearly all of the drug-triggered cases.22BMJ Paediatrics Open. Paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: patterns and outcomes in a retrospective Pakistani cohort Age was associated with poorer outcomes in that cohort, suggesting that very young children may fare worse. Interestingly, the comparative data on Mycoplasma-triggered versus drug-triggered pediatric SJS showed that all children in the infection-triggered group survived, while the drug-triggered group had an actual mortality rate of about 14%, closely matching the predicted rate based on SCORTEN scores.23PubMed Central. Comparative analysis of Mycoplasma Pneumoniae and Drug-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Children That finding adds weight to the clinical impression that infection-triggered SJS in children, while still serious, tends to follow a less lethal course.
Recognizing the Early Signs
One of the most frustrating aspects of SJS is that it often starts with symptoms that look like a garden-variety illness: fever, sore throat, fatigue, body aches. These vague prodromal symptoms typically appear one to three days before any skin involvement, which means the window for early intervention is easy to miss. By the time blisters appear, the immune cascade is already well underway.
The skin rash itself typically begins as flat, dusky-red or purplish spots, often on the trunk before spreading outward. They may have a darker center, sometimes described as target-like, though less well-defined than the classic target lesions seen in a milder condition called erythema multiforme. Painful erosions in the mouth, making eating and drinking excruciating, are usually among the earliest mucosal signs. The eyes often become red, gritty, and swollen around the same time. If you have started a new medication in the past few weeks and develop a painful, spreading rash along with mouth sores and eye irritation, that combination should prompt an urgent visit to an emergency department.
There is no lab test that definitively confirms SJS in the first hours. Diagnosis remains largely clinical, based on the appearance of the rash, mucosal involvement, and the timeline relative to drug exposure. Skin biopsy helps confirm the diagnosis and can show characteristic features like dead skin cells scattered through the outer skin layers, separation of the skin from its base, and inflammatory infiltrates.24Europe PMC / Mayo Clinic Proceedings. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic But biopsy results take time, and treatment should not wait for them.
The Promise and Limits of Genetic Screening
Pharmacogenomic screening represents the most promising prevention strategy. The logic is straightforward: if you can identify people who carry high-risk HLA variants before they take a triggering drug, you can choose an alternative medication and avoid the reaction entirely. This approach has already been implemented successfully for carbamazepine in several countries, where testing for HLA-B*15:02 before prescribing has reduced the incidence of carbamazepine-induced SJS.25PubMed Central. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis
The limits are real, though. Not every drug-SJS association has a known genetic marker. The HLA associations discovered so far explain only a fraction of cases, and many patients who develop SJS carry none of the known risk alleles. There is also a cost-effectiveness calculation: because SJS is so rare, screening millions of patients to prevent a handful of cases means spending a lot of money per case averted. In populations where the risk allele is common, as HLA-B*15:02 is in Southeast and East Asian populations, the math works out favorably. In populations where the allele is rare, it may not. The field is moving toward broader panels that test for multiple HLA risk alleles at once, which could shift the equation by catching more at-risk patients per test.
Beyond genetics, some practical precautions apply to everyone. If you are starting a new medication known to carry SJS risk, particularly the anticonvulsants, allopurinol, or sulfonamide antibiotics, be aware of the early warning signs during the first two months of use. Report any new rash, mouth sores, or eye irritation to your prescriber immediately rather than waiting it out. The speed of drug withdrawal is the single biggest modifiable factor in outcome. A rash that prompts an immediate call to your doctor could be the difference between a mild reaction and a life-threatening one.